Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: A randomized controlled study

Mayo Clinic Proceedings

Volumn 85, Issue 6, 2010, Pages 512-521

  Bogan, Richard K ^a   Cramer Bornemann, Michel A ^b   Kushida, Clete A ^c   Trân, Pierre V ^d   Barrett, Ronald W ^e  

^a Sleep Medicine   (United States)

^b HENNEPIN COUNTY MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY   (United States)

^d Cortex Pharmaceuticals Inc ^*  (United States)

^e XenoPort Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GABAPENTIN ENACARBIL; PLACEBO;

ADULT; ARTICLE; ATTENTION DISTURBANCE; BALANCE DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DISORIENTATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; ELECTROCARDIOGRAPHY; ENDOMETRIOSIS; GASTROENTERITIS; HOT FLUSH; HUMAN; KIDNEY DISEASE; LABORATORY TEST; LETHARGY; LIVER FUNCTION TEST; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MEMORY DISORDER; NAUSEA; PARESTHESIA; PREMATURE EJACULATION; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RESTLESS LEGS SYNDROME; RHINOPHARYNGITIS; SCROTAL PAIN; SIDE EFFECT; SINGLE BLIND PROCEDURE; SLEEP DISORDER; SLEEP WALKING; SOMNOLENCE; URINARY TRACT INFECTION; VERTIGO; VIRUS INFECTION; VITAL SIGN; VOMITING; XEROSTOMIA;

EID: 77952909928     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/mcp.2009.0700     Document Type: Article

References (36)

1. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisir J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology: a report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003;4(2):101-119.
2. Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med. 2005;165(11):1286-1292. (Pubitemid 40989594)
3. Hening W, Walters AS, Allen RP, Montplaisir J, Myers A, Ferini- Strambi L. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med. 2004;5(3):237-246. (Pubitemid 38684217)
4. Kushida CA, Allen RP, Atkinson MJ. Modeling the causal relationships between symptoms associated with restless legs syndrome and the patient-reported impact of RLS. Sleep Med. 2004;5(5):485-488.
5. Winkelman JW, Johnston L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med. 2004;5(1):9-14. (Pubitemid 38145706)
6. Bogan RK, Fry JM, Schmidt MH, Carson SW, Ritchie SY. Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc. 2006;81(1):17-27. (Pubitemid 43054313)
7. Driver-Dunckley ED, Noble BN, Hentz JG, et al. Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clin Neuropharmacol. 2007;30(5):249-255. (Pubitemid 47511504)
8. Ferini-Strambi L, Aarskog D, Partinen M, et al. Effect of pramipexole on RLS symptoms and sleep: a randomized, double-blind, placebo-controlled trial. Sleep Med. 2008;9(8):874-881.
9. Trenkwalder C, Garcia-Borreguero D, Montagna P, et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry. 2004;75(1):92-97. (Pubitemid 38091275)
10. Walters AS, Ondo WG, Dreykluft T, Grunstein R, Lee D, Sethi K. Ropinirole is effective in the treatment of restless legs syndrome: TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord. 2004;19(12):1414-1423.
11. Winkelman JW, Sethi KD, Kushida CA, et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology. 2006;67(6):1034-1039.
12. Garcia-Borreguero D, Larrosa O, de la Llave Y, Verger K, Masramon X, Hernandez G. Treatment of restless legs syndrome with gabapentin: a doubleblind, cross-over study. Neurology. 2002;59(10):1573-1579. (Pubitemid 35387065)
13. Happe S, Klosch G, Saletu B, Zeitlhofer J. Treatment of idiopathic restless legs syndrome (RLS) with gabapentin. Neurology. 2001;57(9):1717-1719. (Pubitemid 33055499)
14. Happe S, Sauter C, Klosch G, Saletu B, Zeitlhofer J. Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome. Neuropsychobiology. 2003;48(2):82-86. (Pubitemid 37176872)
15. Gidal BE, DeCerce J, Bockbrader HN, et al. Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy. Epilepsy Res. 1998;31(2):91-99. (Pubitemid 28361756)
16. Gidal BE, Radulovic LL, Kruger S, Rutecki P, Pitterle M, Bockbrader HN. Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Res. 2000;40(2-3):123-127. (Pubitemid 30339403)
17. Kriel RL, Birnbaum AK, Cloyd JC, Ricker BJ, Jones Saete C, Caruso KJ. Failure of absorption of gabapentin after rectal administration. Epilepsia. 1997;38(11):1242-1244.
18. Stevenson CM, Kim J, Fleisher D. Colonic absorption of antiepileptic agents. Epilepsia. 1997;38(1):63-67.
19. Stewart BH, Kugler AR, Thompson PR, Bockbrader HN. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res. 1993;10(2):276-281.
20. Beydoun A, Fakhoury T, Nasreddine W, bou-Khalil B. Conversion to high dose gabapentin monotherapy in patients with medically refractory partial epilepsy. Epilepsia. 1998;39(2):188-193.
21. Cundy KC, Annamalai T, Bu L, et al. XP13512 [(+/-)-1-([(alpha- isobutanoyloxyethoxy) carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II, improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther. 2004;311(1):324-333.
22. Cundy KC, Branch R, Chernov-Rogan T, et al. XP13512 [(+/-)-1-([(alpha- isobutanoyloxyethoxy) carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I, design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J Pharmacol Exp Ther. 2004;311(1):315-323.
23. Cundy KC, Sastry S, Luo W, Zou J, Moors TL, Canafax DM. Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. J Clin Pharmacol. 2008;48(12):1378-1388.
24. Kushida CA, Becker PM, Ellenbogan AL, Canafax DM, Barrett RW; XP052 Study Group. A randomized, double-blind, placebo-controlled trial of XP13512/GSK1838262 in patients with RLS. Neurology. 2009;72(5):439-446.
25. Hening WA, Allen RP. Restless legs syndrome (RLS): the continuing development of diagnostic standards and severity measures. Sleep Med. 2003;4(2):95-97.
26. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. Adopted 1964. Revised 1996. http: //files.hpci.ch/hh/documents/guidelines/hh-gl-helsinki.pdf. Accessed February 3, 2010.
27. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR. 4th ed, text revised. Arlington, VA: American Psychiatric Association; 2000.
28. National Institute of Mental Health (NIMH). Early clinical drug evaluation unit (ECDEU). clinical global impressions. In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. Revised ed. Rockville, MD: NIMH; 1976:218-222.
29. Allen RP, Kosinski M, Hill-Zabala CE, Calloway MO. Psychometric evaluation and tests of validity of the Medical Outcomes Study 12-item Sleep Scale (MOS sleep). Sleep Med. 2008;10(5):531-539.
30. Hays RD, Stewart AL. Sleep measures. In: Stewart AL, Ware JEJ, eds. Measuring Functioning and Well-being: The Medical Outcomes Study Approach. Durham, NC: Duke University Press; 1992:235-259.
31. Abetz L, Vallow SM, Kirsch J, Allen RP, Washburn T, Earley CJ. Validation of the Restless Legs Syndrome Quality of Life questionnaire. Value Health. 2005;8(2):157-167. (Pubitemid 40525377)
32. Montplaisir J, Karrasch J, Haan J, Volc D. Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial. Mov Disord. 2006;21(10):1627-1635. (Pubitemid 44742190)
33. Trenkwalder C, Stiasny-Kolster K, Kupsch A, Oertel WH, Koester J, Reess J. Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome. Mov Disord. 2006;21(9):1404-1410.
34. Guilleminault C, Cetel M, Philip P. Dopaminergic treatment of restless legs and rebound phenomenon. Neurology. 1993;43(2):445. (Pubitemid 23060290)
35. Kaptchuk TJ, Kelley JM, Conboy LA, et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ. 2008;336(7651):999-1003.
36. Kushida CA, Walters AS, Becker P, et al. A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome. Sleep. 2009;32(2):159-168.